The nation of Zimbabwe has declined a substantial American health deal worth 367 million US dollars (272 million pounds) over five years because of Washington's demand for sensitive biological samples.
The decision became public following a government memo from December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the arrangement was "lopsided".
A government representative later clarified that the US was demanding access to genetic material for research and commercial gain while was unwilling to share the benefits from future vaccines.
"We will now turn to the difficult and regrettable process of scaling back our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had donated more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has appealed for continued talks to secure a deal agreeable to all parties so the nation's vital HIV programme can be sustained.
Wider Context
Zimbabwe's decision follows a comparable case in Kenya, where a court halted a related health funding agreement after legal challenges were raised about the security of citizens' health data.
After resuming office recently, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
The agency had overseen aid for the US government, but Trump claimed its expenditure was "inefficient" and his government was pursuing government-to-government deals to enhance transparency and responsibility.
As per statements, Sixteen African countries have to date signed similar agreements, constituting over $18.3bn in committed funds.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have supported "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration might have yielded significant benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving HIV treatment through American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana said the proposed deal was "asymmetrical".
"Our nation was requested to share its biological resources and data for a long time, with no corresponding assurance of access to any medical innovations – like new medicines or tests – that might result from that provided information," he stated.
"Effectively, our nation would provide the basic resources for scientific discovery without any certainty that the resulting innovations would be available to our population if a future health crisis arise."
Sovereignty and Global Health
He also pointed out that the US's withdrawal from the global health body and its push of one-on-one health agreements were upending frameworks previously set up through the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework designed to deal with future global health emergencies.
"This system is intended to guarantee that when a nation contributes its data, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the resources to create them."
The government's concerns regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We welcome further discussions with our American counterparts on how subsequent collaboration might be structured in a way that honours the sovereignty and dignity of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the government's concerns, but recommended that talks should continue since much of the country's HIV programmes were funded by foreign aid.
"If specific concerns exist, including those relating to information security or agreement terms, these can frequently be addressed via technical clarification and mutually agreed protections," the group commented.
This impasse underscores the complex challenges between accepting crucial international aid and protecting a country's data in an ever more data-driven world.